US Colorectal Cancer Screening Tests Rate to Rise Up to 80% by 2018
The American Cancer Society reports Colon Cancer diagnosis rate has dropped 30% in the US in the last 10 years for those aged 50 years and older. A coalition of more than 70 public, private, and voluntary organizations, led by the American Cancer Society and the Centers for Disease Control and Prevention (CDC), is joining together to focus efforts on dramatically increasing colon screening rates in the US to 80% by 2018.
Colorectal cancer is the third most commonly diagnosed cancer and the third leading cause of cancer death in both men and women in the US. The findings published in Colorectal Cancer Statistics, 2014 report estimates that 136,830 people will be diagnosed with colon cancer and 50,310 people will die from it in 2014. Approximately 5% or 1 in 20 Americans will be diagnosed with colon cancer in their lifetime. As of January 1, 2012, there were almost 1.2 million colon cancer survivors in the US.
Advances in diagnosis and treatment of colorectal cancer have increased survival over the last decade. According to the CDCs Behavioral Risk Factor Surveillance System, nearly 70% of adults aged 50 to 74 years are up to date with colorectal cancer screening. The Colorectal Cancer screening market for US is estimated to be USD 1.4 billion in 2013 and expected to grow ten times in a decade.
This report provides the Colorectal Cancer Screening Tests Market Forecasting Model, offers valuable insights on global evolution, regional variation, and current market trends. The report also provides Company Profiles with Pipeline Products and financials. Most of the products are being developed collaboratively between pharmaceutical and diagnostics companies.
1) Global Market evolution, strategic assessment of Indications market impact analysis, future market and company analysis
2) Competitive Assessment including Pipeline Product approval analysis
3) Coverage of Major Players includes company profiles, financials and major products and services.